Small molecule · Inhibitor of phosphoinositide-3 kinase delta (PIK3CD) · developed by Incyte
Parsaclisib is a small molecule that inhibits the delta isoform of phosphoinositide-3 kinase (PI3K), preventing activation of the PI3K/AKT signaling pathway. It is being studied in non-Hodgkin lymphoma and diffuse large B-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04661007 | Phase 1/2 | Non Hodgkins Lymphoma | Active not recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diffuse Large B-cell LymphomaNon Hodgkins Lymphoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the INCY page.
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →